Ab Science Announces the Results of Phase 2 Study Evaluating Masitinib in Covid-19

Ab Science Announces the Results of Phase 2 Study Evaluating Masitinib in Covid-19

By, Admin 10 July 2024

Overview

AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of PKIs, announces the results of a phase 2 study evaluating masitinib in Covid-19. This randomized (1:1), open-label, phase 2 study (AB20001) was designed to evaluate the safety and efficacy of masitinib plus isoquercetin in hospitalized patients with moderate Covid-19 (WHO 7-point ordinal scale level 4) or severe Covid-19 (level 5). The study initially planned to recruit 200 patients (over 18 years of age with no upper age limit). The primary objective was to improve the clinical status of patients after 15 days of treatment, as measured by the WHO 7-point ordinal scale. Following a DSMB recommendation, decision was taken to continue the study only in level 4 patients (i.e. hospitalized patients with oxygen supply <6 L/min with SpO2 maintained =92%).

Patient Enrolment

  • The study could not recruit the planned 200 patients. The decision was therefore taken to stop inclusion after 95 patients were randomized. 
  • The objective was to detect a trending treatment effect with 95 patients that would translate into a significant effect when simulating the same effect with the planned enrolment of 200 patients. 
  • If this objective was reached, then the conclusion would be that it is worth continuing to evaluate masitinib as an agent in the treatment of Covid in patients hospitalized with moderate need of oxygen.

Study Results

  • The study showed an odds ratio of 2.4 in favour of the treatment arm after 15 days of treatment, superior to the odds ratio of 2.2 initially hypothesized, with p=0.038 simulated with 200 patients and p=0.072 detected with 95 patients recruited. 
  • Sensitivity analyses at day 12, 13 and 14 with 95 patients recruited displayed a p-value of respectively p=0.016, 0.019, 0.018 and odds ratio 3.2, 3.2 and 3.4. 
  • This was due to improvement of certain placebo patients at day 15 but not before. The safety was in line with the known safety profile of masitinib.

Words from MD: AB Science

Professor Olivier Hermine, MD, president of the scientific committee of AB Science and member of the Académie des Sciences in France said: “This result confirms the anti-inflammatory activity of masitinib, by controlling activated macrophages and mast cells involved in Covid. In addition, several publications highlighted the capacity of masitinib to act as an indirect broad antiviral agent against Covid. With this result, masitinib can be considered a drug of choice to be evaluated in the context of a future pandemic”.

Words from CEO: AB Science

Alain Moussy, co-founder and CEO of AB Science said: “We are thankful to the European Investment Bank for having funded this development of masitinib in Covid, and to our partner Quercegen for having proposed to combine masitinib with isoquercetin. This result warrants further evaluation and we will discuss such opportunity with public entities or private partners.”

Sbout AB Science

Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signalling pathways within cells.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!